Bienaime Jean Jacques's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Mar 14, 2023
- Accession no.
- 0001567619-23-005059
- Filed
- Mar 14, 2023
- Trade date
- Mar 10-13, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.11M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bienaime Jean JacquesCIK 0001221590 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2023 | Common Stock | MOption exerciseAcquired | +15,000 | $67.81 | +$1,017,150 | 502,856 | Direct | |
| Mar 10, 2023 | Common Stock | SSaleDisposed | −15,000 | $92.28 | −$1,384,200 | 487,856 | Direct | |
| Mar 13, 2023 | Common Stock | MOption exerciseAcquired | +8,000 | $67.81 | +$542,480 | 495,856 | Direct | |
| Mar 13, 2023 | Common Stock | SSaleDisposed | −8,000 | $90.45 | −$723,600 | 487,856 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2023 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 157,130 | Direct | |
| Mar 13, 2023 | Common Stock | MOption exerciseDisposed | −8,000 | $0.00 | $0 | 149,130 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.